Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Zug, Switzerland, Feb. 1 (Korea Bizwire) — Lupin is pleased to announce that NaMuscla® (mexiletine) has been launched in Germany and the United Kingdom (UK). NaMuscla® is approved across the European Union (EU) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. These disorders are a group of rare, inherited neuromuscular conditions [...]